The FDA approval of oral decitabine/cedazuridine with venetoclax is significant not for its new mechanism, which mimics existing IV therapies, but for its all-oral formulation. This shift dramatically improves patient quality of life by reducing the time AML patients must spend in hospital settings for infusions, labs, and other procedures.
The use of lower-intensity hypomethylating agents (HMA) with venetoclax is expanding beyond just chemo-ineligible AML patients. Clinicians now consider it a primary strategy for chemotherapy-fit patients if their tumor genomics suggest it may be as good or better than intensive chemo, marking a significant shift in treatment decision-making.
Despite the convenience of an all-oral regimen, its initial use is not a simple outpatient affair. The high risk of neutropenic infections and transfusion needs during the first cycle often necessitates inpatient admission for close monitoring, a cautious approach followed at major cancer centers to manage early, severe hematologic adverse events.
While adding venetoclax to a hypomethylating agent is standard for many AML patients, it is not recommended for those with P53 mutations. Despite potentially higher initial response rates, the combination does not translate into improved overall survival for this specific genetic subset, making it an ineffective long-term strategy.